Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 7Gynecologic 6Other hematologic neoplasm 5Genitourinary 5Breast 5Lymphoid 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Saline Solution × Tumor-Agnostic × Clear all
NCT02453334 2021-05-11

IRON CLAD

American Regent, Inc.

Phase 3 Completed
244 enrolled 33 charts
Tumor-Agnostic

Neoplasms

NCT01874561 2016-10-10

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Achieve Life Sciences

Phase 1 Completed
155 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡